GlassScriptPhysician profile
Silvio A Mandara
NPI 1134292881
$4,436.24
in general payments reported to CMS, 2019-2025
32 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $479 · 2021: $723 · 2022: $1,211 · 2023: $469 · 2024: $339 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $874.11 | 2019-2023 | |
| Amgen INC. | $618.41 | 2020-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $447.61 | 2019-2025 | Veozah |
| Novo Nordisk INC | $254.21 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.57 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $192.19 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $190.57 | 2021-2022 | |
| Avion Pharmaceuticals | $189.47 | 2019-2022 | |
| Pfizer INC. | $180.23 | 2019-2023 | |
| Allergan, INC. | $168.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $111.98 | 2019-2020 | |
| Exact Sciences Corporation | $111.61 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.08 | 2019-2022 | |
| Csl Behring | $76.42 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $73.93 | 2019 | |
| Mayne Pharma Commercial LLC | $62.54 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $42.93 | 2022 | |
| Endo Pharmaceuticals INC. | $40.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $39.52 | 2019 | |
| Eisai INC. | $38.39 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $37.05 | 2019 | |
| Medtronic, INC. | $36.73 | 2021 | |
| Duchesnay USA Incorporated | $36.21 | 2019 | |
| Therapeuticsmd, INC. | $35.94 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $32.63 | 2020-2021 | |
| Amarin Pharma, INC. | $31.74 | 2019-2021 | |
| Lilly USA, LLC | $28.09 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $25.08 | 2022 | |
| Upsher-Smith Laboratories LLC | $20.00 | 2022 | |
| Millicent US INC | $17.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvio Mandara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.